{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:46:09Z","timestamp":1773110769038,"version":"3.50.1"},"reference-count":0,"publisher":"Portland Press Ltd.","issue":"s25","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1991,10,1]]},"abstract":"<jats:p>1. An increasing body of data suggests that the anti-haemostatic as well as the ulcerogenic actions of aspirin and other non-steroidal anti-inflammatory drugs may be operative when patients present with haematemesis and melaena.<\/jats:p>\n               <jats:p>2. We therefore developed methods to allow separate evaluation of the erosive and anti-haemostatic actions of aspirin in the human gastric mucosa. Volunteer subjects took 300 mg of aspirin daily in the morning or 600 mg of aspirin four times a day for 5 days under blinded randomized conditions. Changes in spontaneous gastric microbleeding, endoscopic signs of injury, spontaneous bleeding per gastric erosion, biopsy-induced bleeding and eicosanoids were studied.<\/jats:p>\n               <jats:p>3. Both doses of aspirin significantly inhibited gastric mucosal synthesis of prostaglandin E2 and reduced the serum thromboxane concentration. Erosions developed and regressed rapidly; compared with baseline 300 mg of aspirin daily in the morning caused substantial numbers of gastric erosions to develop (mean 5.3, 95% confidence limits 2.7\u201310.2) but this was significantly less than that caused by 600 mg of aspirin four times a day (10.9, 7.2\u201316.5, P &amp;lt; 0.05). The presence of erosions was associated with enhanced spontaneous bleeding, but only during aspirin administration.<\/jats:p>\n               <jats:p>4. Aspirin significantly increased bleeding induced by mucosal biopsy and was associated with significant enhancements in the rate of bleeding per gastric erosion. Bleeding rate per erosion but not biopsy-induced bleeding showed a significant dose-related increase with 600 mg of aspirin four times a day. Enteric coating reduced endoscopic signs of injury, but did not affect the impaired haemostasis caused by aspirin.<\/jats:p>\n               <jats:p>5. We conclude that aspirin can be shown to have both erosive and anti-haemostatic effects in the human stomach. Each can be evaluated separately in our model system. Both are potential therapeutic targets for the prevention of major upper-gastrointestinal bleeding caused by aspirin and probably other non-steroidal antiinflammatory drugs.<\/jats:p>","DOI":"10.1042\/cs0810565","type":"journal-article","created":{"date-parts":[[2015,8,7]],"date-time":"2015-08-07T11:33:17Z","timestamp":1438947197000},"page":"565-573","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach"],"prefix":"10.1042","volume":"81","author":[{"given":"C. J.","family":"Hawkey","sequence":"first","affiliation":[{"name":"Department of Therapeutics, Queen's Medical Centre, University Hospital, Nottingham, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Hawthorne","sequence":"additional","affiliation":[{"name":"Department of Therapeutics, Queen's Medical Centre, University Hospital, Nottingham, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Hudson","sequence":"additional","affiliation":[{"name":"Department of Therapeutics, Queen's Medical Centre, University Hospital, Nottingham, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. T.","family":"Cole","sequence":"additional","affiliation":[{"name":"Department of Therapeutics, Queen's Medical Centre, University Hospital, Nottingham, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y. R.","family":"Mahida","sequence":"additional","affiliation":[{"name":"Department of Therapeutics, Queen's Medical Centre, University Hospital, Nottingham, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. K.","family":"Daneshmend","sequence":"additional","affiliation":[{"name":"Department of Therapeutics, Queen's Medical Centre, University Hospital, Nottingham, U.K."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","container-title":["Clinical Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/81\/s25\/565\/745044\/cs0810565.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/clinsci\/article-pdf\/81\/s25\/565\/745044\/cs0810565.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T23:59:50Z","timestamp":1638403190000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/clinsci\/article\/81\/s25\/565\/97316\/Separation-of-the-impairment-of-haemostasis-by"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1991,10,1]]},"references-count":0,"journal-issue":{"issue":"s25","published-print":{"date-parts":[[1991,10,1]]}},"URL":"https:\/\/doi.org\/10.1042\/cs0810565","relation":{},"ISSN":["0144-9664"],"issn-type":[{"value":"0144-9664","type":"print"}],"subject":[],"published":{"date-parts":[[1991,10,1]]}}}